PURPOSE OF REVIEW This article is an update from the article on antiepileptic drug (AED)
therapy published in the last Continuum issue on epilepsy and is intended to cover the vast …

Women with epilepsy (WWE) wishing for a child represent a highly relevant subgroup of
epilepsy patients. The treating epileptologist needs to delineate the epilepsy syndrome and …

The antiepileptic drug lacosamide [(R)-2-acetamido-N-benzyl-3-methoxypropanamide], a
chiral functionalized amino acid, was originally identified by virtue of activity in the mouse …

Abstract EDITOR'S NOTE The article “Update on Antiseizure Medications 2022” by Dr Abou-
Khalil was first published in the February 2016 Epilepsy issue of Continuum: Lifelong …

This study aimed at evaluating the effects of eslicarbazepine, carbamazepine (CBZ),
oxcarbazepine (OXC) and lacosamide (LCM) on the fast and slow inactivated states of …

Objective To evaluate the efficacy and safety of adjunctive eslicarbazepine acetate (ESL) in
patients with refractory partial‐onset seizures. Methods This randomized, placebo …

This review focuses on the evolution of approaches to dosing of antiepileptic drugs (AEDs)
in clinical practice through history. There has been a shift in the view of treatment of …

Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Objective To assess the efficacy and safety of eslicarbazepine acetate (ESL) as
monotherapy in North American patients with partial‐onset seizures (POS). Methods This …

Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the
European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health …